Cosmo and Glenmark receives market authorization of Winlevi in Europe
Winlevi is authorized in EU for the treatment of acne vulgaris
Winlevi is authorized in EU for the treatment of acne vulgaris
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
India presents one of the world’s largest untapped opportunities for neurovascular screening
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer
Subscribe To Our Newsletter & Stay Updated